FDA's New Quality Management System Regulation Raises the Bar for Inspection Readiness
FDA's Quality Management System Regulation (QMSR), which became effective on February 2, 2026, represents one of the most significant updates to medical device quality system requirements in nearly three decades. By incorporating ISO 13485:2016 into 21 CFR Part 820, the FDA has further aligned US quality system expectations with internationally recognized standards while maintaining certain FDA-specific regulatory requirements.
For many manufacturers, the transition is not simply a regulatory update. It requires organizations to evaluate whether their existing quality management system truly aligns with the expectations FDA inspectors will now use during inspections and when reviewing manufacturing-related information submitted as part of premarket applications.
While organizations certified to ISO 13485 may have a strong foundation, certification alone does not necessarily demonstrate full compliance with QMSR. Likewise, companies operating under legacy Part 820 procedures should not assume that only minor documentation updates are required.
As manufacturers assess their readiness, several common areas warrant particular attention.
One of the most significant shifts under QMSR is the increased emphasis on risk-based decision making.
Many organizations perform risk analyses during product development but fail to integrate risk management across the entire quality management system. FDA expects risk considerations to influence supplier controls, CAPA activities, complaint investigations, process validation, change management, and ongoing production activities.
A disconnected approach to risk management can create inconsistencies that become apparent during inspections.
Questions to ask:
Is risk management incorporated into quality processes beyond product design?
Are quality decisions consistently supported by documented risk evaluations?
Do procedures clearly demonstrate a risk-based approach?
Design and Development remain one of the most scrutinized aspects of medical device inspections.
Organizations often discover that design inputs, verification, validation, design reviews, and design changes are documented independently rather than as a cohesive design and development file (formally the Design History File).
Under QMSR, inspectors are likely to place increased emphasis on demonstrating clear traceability throughout the design lifecycle.
Manufacturers should confirm that design documentation clearly links:
User needs
Design inputs
Design outputs
Verification activities
Validation activities
Design changes
Risk management documentation
Gaps in traceability can slow inspections and complicate premarket reviews.
Supplier management has become increasingly important as manufacturers rely on complex global supply chains.
Many supplier qualification programs continue to classify vendors primarily on purchasing categories rather than the actual risk posed to product quality and patient safety.
Manufacturers should evaluate whether supplier oversight appropriately reflects:
Supplier criticality
Component or contract manufacturing risk
Performance history
Monitoring activities
Re-evaluation criteria
A documented, risk-based supplier management program better aligns with QMSR expectations.
Corrective and Preventive Action (CAPA), which is now stated as Correct Action and Preventive Action per QMSR, remains one of FDA's primary indicators of quality system maturity.
Organizations frequently close a Corrective Action after correcting an immediate issue without adequately investigating root cause or verifying long-term effectiveness.
Under QMSR, FDA continues to expect Corrective Action/Preventive Action system that:
Identifies systemic issues
Investigate true root causes preferably using applicable tools
Implement meaningful corrective actions and addresses preventive actions
Verify effectiveness over time
Drive continuous improvement
An effective "CAPA" program should demonstrate organizational learning, not simply issue resolution.
Documentation inconsistencies often become evident during inspections, particularly following years of incremental procedural updates.
Common issues include:
Conflicting procedures including not being updated to QMSR
Outdated forms
Inconsistent document revisions
Missing links between procedures
Duplicate quality records
While individual discrepancies may appear minor, collectively they can suggest weaknesses in document control and quality system governance.
A comprehensive documentation review is often one of the fastest ways to identify readiness gaps before an FDA inspection.
Many organizations perform annual internal audits using historical Part 820 checklists.
However, audit programs should now evaluate whether the quality management system aligns with the requirements and intent of QMSR.
Effective readiness audits assess not only procedural compliance but also whether quality processes function together as an integrated system.
Organizations should consider whether their internal audits evaluate:
Risk-based processes or approach
Cross-functional interactions
Objective evidence of effectiveness
Management review outputs, which can now be seen by FDA
Continuous improvement activities
A QMSR-focused audit often uncovers opportunities that routine compliance audits overlook.
Management review meetings frequently emphasize operational metrics while spending less time evaluating the overall effectiveness of the quality management system.
QMSR reinforces the importance of leadership oversight and continual improvement.
Management review should provide documented evidence that top leadership evaluates:
Quality objectives
Audit results
CAPA trends
Supplier performance
Customer and Post-Market feedback
Process performance and product conformity
Resource needs
Opportunities for improvement
Regulatory Compliance
Product improvements related to customer requirements
Strong top management oversight, including a risk-based approach, demonstrates an organization's commitment to maintaining an effective quality management system rather than simply meeting compliance requirements.
FDA has made it clear that manufacturers are expected to assess their quality management systems for alignment with QMSR. Organizations that wait until an inspection occurs to identify gaps may face unnecessary delays, increased remediation efforts, or regulatory compliance observations.
A structured QMSR readiness assessment provides an objective evaluation of your current quality system, identifies areas requiring attention, and establishes a practical roadmap for compliance before FDA inspectors arrive.
For organizations already compliant with legacy 21 CFR Part 820 requirements or ISO 13485, many gaps can be addressed efficiently through targeted remediation and documentation updates. Taking a proactive approach now can reduce regulatory risk while strengthening overall quality system performance.
ProPharma helps medical device manufacturers evaluate their readiness for FDA's new Quality Management System Regulation through comprehensive QMSR Gap and Readiness Assessments. Our experts review your existing quality management system against current regulatory expectations, identify compliance gaps, and provide practical recommendations for remediation.
For organizations requiring additional support, we also assist with implementing corrective actions, updating quality system documentation, and completing quality activities necessary to support FDA market readiness, including WRAP system requirements.
Whether your organization is transitioning from legacy Part 820 compliance or looking to validate alignment with QMSR before your next FDA inspection, our experts can help you build a practical roadmap to compliance and continuous quality improvement.